Efeito modulatório da miricetina sobre a síndrome metabólica e o comportamento de camundongos com obesidade hipotalâmica

Abstract

Flavonoids could be indicated as potential preventive therapy for obesity, metabolic syndrome and even their comorbidities. Myricetin is a flavonoid known for its hypoglycemic and anti-obesity effects, as well as its great scavenger capacity. Rodent obesity induced by monosodium L-glutamate (MSG) is a model of hypothalamic obesity which develops early hyperinsulinemia and mimetizes DM 2, obesity, dyslipidemia, NAFLD/NASH and cognitive deficit. Thus, this study aimed to investigate whether myricetin can revert or ameliorate metabolic and behavioral features in MSG-induced obesity. Newborn mice were treated with MSG subcutaneously (4 mg/kg) on alternate days in the first 10 days of life. After reaching 90 days of life, a group of MSG obese mice were treated with myricetin (50 mg/kg) or distilled water. Control animals, previously treated with neonatal subcutaneous injection of 0.9% saline solution, were treated with vehicle also. After 4 weeks of treatment, mice were submitted to behavior tests: open field maze, elevated plus maze and Morris water maze. After all tests were performed, animals were euthanized for collection of liver, serum and adipose tissue depots, for further analysis. Myricetin treatment was able to ameliorate hyperglycemia, insulin sensitivity, triglycerides levels, liver steatosis and exploratory behaviors. However, MSG exhibited cognitive impairment that was not improved by myricetin treatment.